Get the app
NSEHealthcare

Neuland Laboratories Limited (NEULANDLAB)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹22,665.00+0.18%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
₹642 cr
Revenue YoY
+119.2%
Net profit
₹148 cr
Profit YoY
+962.4%
EPS
₹115.10
EPS estimate
₹60.01
Net margin
23.0%

EPS came in at 115.10 against a street estimate of 60.01 — a beat of 91.8%.

Key statistics

Market cap
₹30,535 cr
P/E
61.4
Forward P/E
18.4
P/B
15.88
Book value
₹1,461.02
EPS (TTM)
₹387.36
52-week high
₹24,225.00
52-week low
₹11,478.79
50-day MA
₹21,050.80
200-day MA
₹16,423.23
Beta
-0.32

Analyst view

with an average price target of ₹24,334.75.

Shareholding

Promoters
37.74%
Institutions
28.24%

Recent filings & reports

DocumentDate
Q1 FY27 earnings call
NEULAND LABORATORIES LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Total Income: INR 650.1 crores (Q1 FY27) vs INR 300.6 crores (Q1 FY26) –
2026-08-10
Investor presentation · Q1 FY27
NEULAND LABORATORIES LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Total Income Q1FY27: Rs. 650.1 crore (116.3% YoY growth; down 17.6%
2026-08-05
Quarterly results · Q1 FY27
NEULAND LABORATORIES LIMITED – Q1 FY27 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Income: Rs. 650.1 crore in Q1 FY27, up 116.3% year-on-year from Rs
2026-08-05
Annual report FY2026
NEULAND LABORATORIES LIMITED - FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue milestone: Company crossed ₹1,000 crore in previous year; FY 2025-26 sa
2026-07-09
Q4 FY26 earnings call
NEULAND LABORATORIES LIMITED – Q4 & FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: INR 788.7 crores, up 134.9% YoY (vs INR 335.8 crores i
2026-05-16
Quarterly results · Q4 FY26
NEULAND LABORATORIES LIMITED – SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Annual Revenue (FY 2025-26): Rs. 2,02,298.54 lakhs (consolidated), up
2026-05-12
Investor presentation · Q4 FY26
NEULAND LABORATORIES LIMITED – INVESTOR SUMMARY Q4FY26 & FY26 Results (May 12, 2026) --- HEADLINE NUMBERS • Total Income FY26: Rs. 2,053.1 crore (3
2026-05-12
Q3 FY26 earnings call
NEULAND LABORATORIES LIMITED – Q3 FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 Total Income: INR 447.8 crores, up 11.4% YoY (vs INR 401.9 crores in Q3 FY
2026-02-13

Readable in the app.

Corporate actions

ActionDetailDate
Dividend₹34 / share
ex-date Jul 24, 2026
2026-07-24

Deals & corporate news

AnnouncementDate
Enhancement of manufacturing capacity announced
Disclosure under Regulation 30 of SEBI Listing Regulations - Enhancement of manufacturing capacity
2026-08-05

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neuland Laboratories Limited — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.